BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR

BMS-754807 is a potent and reversible inhibitor of the insulin-like growth factor 1 receptor/insulin receptor family kinases (Ki, <2 nmol/L). It is currently in phase I development for the treatment of a variety of human cancers. BMS-754807 effectively inhibits the growth of a broad range of human tumor types in vitro, including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, gastric), and hematopoietic (multiple myeloma and leukemia) tumor cell lines (IC50, 5–365 nmol/L); the compound caused apoptosis in a human rhabdomyosarcoma cell line, Rh41, as shown by an accumulation of the sub-G1 fraction, as well as by an increase in poly ADP ribose polymerase and Caspase 3 cleavage. BMS-754807 is active in vivo in multiple (epithelial, mesenchymal, and hematopoietic) xenograft tumor models with tumor growth inhibition ranging from 53% to 115% and at a minimum effective dose of as low as 6.25 mg/kg dosed orally daily. Combination studies with BMS-754807 have been done on multiple human tumor cell types and showed in vitro synergies (combination index, <1.0) when combined with cytotoxic, hormonal, and targeted agents. The combination of cetuximab and BMS-754807 in vivo, at multiple dose levels, resulted in improved clinical outcome over single agent treatment. These data show that BMS-754807 is an efficacious, orally active growth factor 1 receptor/insulin receptor family–targeted kinase inhibitor that may act in combination with a wide array of established anticancer agents. [Mol Cancer Ther 2009;8(12):3341–9]

[1]  C. Osborne,et al.  Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. Chakraborty,et al.  Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. , 2008, Cancer research.

[3]  M. Pollak,et al.  Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells , 2005, Breast Cancer Research.

[4]  G. Trainor,et al.  Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development. , 2009, Journal of medicinal chemistry.

[5]  A. Tolcher,et al.  A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors , 2007 .

[6]  A. Costantino,et al.  Insulin Receptor Isoform A, a Newly Recognized, High-Affinity Insulin-Like Growth Factor II Receptor in Fetal and Cancer Cells , 1999, Molecular and Cellular Biology.

[7]  S. Weroha,et al.  IGF-1 Receptor Inhibitors in Clinical Trials—Early Lessons , 2008, Journal of Mammary Gland Biology and Neoplasia.

[8]  H. Masoudi,et al.  Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. , 2008, Cancer research.

[9]  S. Thomson,et al.  Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. , 2008, Cancer research.

[10]  D. Leroith,et al.  Insulin and Insulin-Like Growth Factor I Receptors: Similarities and Differences in Signal Transduction , 2004, Hormone Research in Paediatrics.

[11]  D. Yee,et al.  Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. , 2007, Cancer research.

[12]  C. Erlichman,et al.  HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924 , 2008, Molecular Cancer Therapeutics.

[13]  J. Flier,et al.  Ligand-binding properties of the two isoforms of the human insulin receptor. , 1993, Endocrinology.

[14]  J. Stock,et al.  Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. , 2003, The Journal of clinical investigation.

[15]  Adrian V. Lee,et al.  Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. , 2005, Cancer research.

[16]  David Bebbington,et al.  VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo , 2004, Nature Medicine.

[17]  N. Webster,et al.  Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer. , 1996, Cancer research.

[18]  G M Clark,et al.  Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. , 1993, Cancer research.

[19]  D. Yee,et al.  Disrupting insulin-like growth factor signaling as a potential cancer therapy , 2007, Molecular Cancer Therapeutics.

[20]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[21]  Mark W Tengowski,et al.  Combination Therapy Enhances the Inhibition of Tumor Growth with the Fully Human Anti–Type 1 Insulin-Like Growth Factor Receptor Monoclonal Antibody CP-751,871 , 2005, Clinical Cancer Research.

[22]  Y. Lu,et al.  Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). , 2001, Journal of the National Cancer Institute.

[23]  H. Hsieh,et al.  Aurora kinase inhibitors in preclinical and clinical testing. , 2009, Expert opinion on investigational drugs.

[24]  R. Knegtel,et al.  Crystal Structure of Aurora-2, an Oncogenic Serine/Threonine Kinase* , 2002, The Journal of Biological Chemistry.

[25]  R. Baserga,et al.  The insulin-like growth factor I receptor: a key to tumor growth? , 1995, Cancer research.

[26]  L. Paz-Ares,et al.  Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC) , 2007 .

[27]  Tony Hunter,et al.  Epidermal Growth Factor-Induced Tumor Cell Invasion and Metastasis Initiated by Dephosphorylation and Downregulation of Focal Adhesion Kinase , 2001, Molecular and Cellular Biology.

[28]  R. Baserga.  The insulin-like growth factor-I receptor as a target for cancer therapy , 2005, Expert opinion on therapeutic targets.

[29]  S. Hankinson,et al.  Insulin-like growth factors and neoplasia , 2004, Nature Reviews Cancer.

[30]  P. Elizalde,et al.  Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells , 2001, Oncogene.

[31]  E. Gehan,et al.  A generalized two-sample Wilcoxon test for doubly censored data. , 1965, Biometrika.

[32]  Ryuji Kobayashi,et al.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. , 2005, Cancer research.

[33]  H. Friesen,et al.  Hormone binding by human mammary carcinoma. , 1977, Cancer research.

[34]  A. Tolcher,et al.  Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  A. Tolcher,et al.  A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor1 receptor) antagonist, in patients(pts) with advanced solid tumor(ST) , 2008 .

[36]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[37]  S. Davidsen,et al.  Insulin-like Growth Factor-1 Receptor and ErbB Kinase Inhibitor Combinations Block Proliferation and Induce Apoptosis through Cyclin D1 Reduction and Bax Activation* , 2008, Journal of Biological Chemistry.

[38]  M. Rubini,et al.  The role of the IGF‐I receptor in the growth and transformation of mammalian cells , 1994, Cell proliferation.

[39]  F. Peruzzi,et al.  The IGF‐1 receptor in cancer biology , 2003, International journal of cancer.

[40]  A. Adjei,et al.  Phase I dose escalation study of the anti-IGF-1R monoclonal antibody CP-751,871 in patients with refractory solid tumors , 2007 .